R&D channel feed

Bio­Marin eyes FDA ap­proval as PhI­II re­sults emerge in most com­mon form of dwarfism

6 years ago

Wave's Duchenne pro­gram comes to a screech­ing halt — now all eyes will be on Hunt­ing­ton's

6 years ago

Rare skin dis­ease biotech eyes $16 mil­lion IPO as tri­al re­sults come in and cash runs out

6 years ago

BeiGene's BTK in­hibitor fails to beat mar­ket leader Im­bru­vi­ca in key head-to-head study

6 years ago
China

Paul Bion­di is jump­ing from Bris­tol-My­ers to the elite team man­ag­ing Flag­ship's star­tups — with new­co plans of his own

6 years ago

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle biotech

6 years ago

PhII fail­ure in rare neu­rode­gen­er­a­tive dis­ease? No mat­ter, Bio­gen will mo­tor on in Alzheimer's

6 years ago

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

6 years ago

Roche's triplet in­volv­ing Tecen­triq clears the PFS bar for melanoma when added to BRAF/MEK com­bo

6 years ago
Pharma

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

6 years ago
FDA+

KRAS analy­sis vaults Mer­ck­'s flag­ship Keytru­da back in­to the spot­light

6 years ago

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

6 years ago

Cor­re­vio is putting it­self up on the auc­tion block af­ter FDA re­view pan­el points to an­oth­er re­jec­tion

6 years ago

In a key step for psy­che­del­ic re­search, mag­ic mush­room com­pound clears first clin­i­cal safe­ty hur­dle

6 years ago

For sale: Long-act­ing PhI­II GLP-1 di­a­betes drug that’s way be­hind ri­vals, now spurned by Sanofi

6 years ago

FDA in-house re­view spot­lights an is­sue with one of Hori­zon's end­points but notes ef­fi­ca­cy for lead drug

6 years ago

Seat­tle Ge­net­ics de­tails pos­i­tive OS and PFS da­ta for tu­ca­tinib in breast can­cer

6 years ago

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

6 years ago

Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

6 years ago

De­sert­ed by Astel­las and Mer­ck, lit­tle Cor­re­vio still can't win over FDA pan­el con­cerned with its AFib drug's safe­ty

6 years ago

New trade deal knocks out long-sought bi­o­log­ics pro­tec­tions for drug­mak­ers

6 years ago

With loom­ing su­per­bug cri­sis, Iterum miss­es in a key an­tibi­ot­ic tri­al — and its shares tum­ble

6 years ago

Lit­tle Leo Phar­ma en­ters the prize-fight ring with pos­i­tive PhI­II atopic der­mati­tis da­ta. Now they just have to beat Dupix­ent

6 years ago

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

6 years ago
Pharma
First page Previous page 218219220221222223224 Next page Last page
A service from the Financial Times